IMMUNIS.AI
Immunis AI is the developer of a non-invasive blood-based immunogenomic platform. The startup performs detailed genomic analysis of patient blood samples to understand diseases that individuals may be harbouring and the body's immune response to those diseases. The platform's initial focus is on oncology, with plans to expand to other diseases and treatments in the future.
IMMUNIS.AI
Social Links:
Industry:
Artificial Intelligence Health Care Health Diagnostics Wellness
Founded:
2012-01-01
Address:
Royal Oak, Michigan, United States
Country:
United States
Website Url:
http://www.immunis.ai
Total Employee:
1+
Status:
Active
Contact:
+1 248 918 0468
Email Addresses:
[email protected]
Official Site Inspections
http://www.immunis.ai
- Host name: server-54-240-184-4.ord51.r.cloudfront.net
- IP address: 54.240.184.4
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
More informations about "Immunis.AI"
Immunis
Immunis.AI is a privately held company committed to making a global impact by empowering patients and their physicians with actionable information for disease management.. Our …See details»
Immunis.AI - Crunchbase Company Profile & Funding
Organization. Immunis.AI . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Immunis.AI is an immunogenomics company. …See details»
Immunis.AI 2025 Company Profile: Valuation, Funding …
Immunis.AI General Information Description. Developer of a non-invasive blood-based immunogenomic platform discovery platform designed to detect cancer. …See details»
Immunis.ai Company Profile | Royal Oak, MI - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Immunis.ai of Royal Oak, MI. Get the latest business insights from Dun & Bradstreet.See details»
Immunis.AI - LinkedIn
Immunis.AI is a privately held company committed to making a global impact by empowering patients and their physicians with actionable information for disease management. Our …See details»
Immunis - Crunchbase Company Profile & Funding
Organization. Immunis . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... Immunis a private biotechnology company developing a novel treatment for age and disease …See details»
Immunis.AI - Funding, Financials, Valuation & Investors - Crunchbase
Sep 29, 2021 Immunis.AI is an immunogenomics company. How much funding has this organization raised over time? ShowSee details»
Immunis.AI - 2025 Company Profile, Funding & Competitors - Tracxn
Feb 26, 2025 Immunis.AI. has raised a total funding of $40M over 2 rounds. Its first funding round was on Sep 11, 2019. What are the most recent funding rounds of Immunis.AI? Its latest …See details»
Immunis - Company Profile
Immunis The secretome is the total set of factors secreted from a cell including proteins, lipids, growth factors, cytokines, and exosomes. A well-functioning immune system is necessary for …See details»
Immunis.Ai, Inc. in Corvallis OR - Company Profile - Corporation Wiki
Immunis.Ai, Inc. Overview. Immunis.Ai, Inc. filed as a Statement & Designation By Foreign Corporation in the State of California on Friday, December 27, 2019 and is approximately five …See details»
Immunis.AI Company Profile - Office Locations, Competitors
Immunis.AI is an immunogenomics company that specializes in surveillance tests and early detection assays. Its platform enables immune defense systems, analytical methods, AI, and …See details»
Immunis.AI Achieves Development Milestones and Additional …
Sep 29, 2021 IMMUNIS.AI is a privately held immunogenomics company with a patented liquid biopsy platform that offers unique insights into disease biology and individualized assessment. …See details»
Immunis.AI Chosen by Amazon Web Services to Showcase its …
Oct 5, 2021 IMMUNIS.AI is a privately held immunogenomics company with a patented liquid biopsy platform that offers unique insights into disease biology and individualized assessment. …See details»
Immunis.AI | Mission Cloud
Immunis.AI plans to replicate its successful blueprint across many clinical studies throughout 2021 and beyond, as it develops and commercializes its products. Mission is continuing to support …See details»
Immunis.AI Reaches $40M in Funding, Hits Key Milestones for …
Sep 30, 2021 Immunis.AI now anticipates launching its test in late 2022. "Immunis has developed a platform that harnesses the power of the immune system, achieving potent signal …See details»
Immunis - Remiges Ventures
Immunis is a private biotechnology company developing a novel immunomodulatory secretome product for the various manifestations of age and disease-related immune decline. The …See details»
Immunis - Funding, Financials, Valuation & Investors - Crunchbase
How much funding has this organization raised over time? Show . Announced Date ... obfuscated. Ironwood Ventures: Aug 3, 2022: Series A - Immunis . 2: obfuscated. obfuscated. Remiges …See details»
Federal government announces support for cutting-edge, AI- and …
1 day ago Federal government announces support for cutting-edge, AI- and robotics-enabled cell and gene therapy manufacturing . From: Innovation, ... OmniaBio Inc. is a technology …See details»
Immunis.AI Announces Publication, in The Journal of Urology, of …
Mar 1, 2024 Immunis.AI Announces Publication, in The Journal of Urology, of Results from Blood-Based Immune Profiling Study for Prostate Cancer Patients Business Wire Fri, Mar 1, …See details»
Novel biologics in support of muscle and immune health.
Revolutionizing Longevity with Multi-active Biologics Immunis is developing novel, multi-active biologics to address the complexities of age and immune-driven diseases, thereby promoting a …See details»